Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
Pieris AG and AlgoNomics NV announced that AlgoNomics' proprietary platform for T-cell epitope identification, Epibase®, revealed that Pieris' human binding proteins Anticalins® intrinsically have an immunogenicity level comparable to the wild-type human lipocalin, as witnessed by a comparable number and promiscuity of the T-cell epitopes identified.
According to the company, Epibase® analysis supports Pieris in the selection and optimization of Anticalins® with favorable properties including the lowest possible immunogenicity both in their internal projects and in collaborative projects with its partners.
"Pieris purposely selected human lipocalin scaffolds for therapeutic use because of their intrinsic properties. The chosen human lipocalins are small, non-glycosylated, highly stable monomeric binding proteins present in significant amounts in blood and other bodily fluids. Anticalins® are therefore expected to exhibit a low immunogenicity potential upon repeated parenteral use", says Dr. Andreas Hohlbaum, Pieris' Director of Science and Preclinical Development.
Other news from the department business & finance
